EVIDENCE-BASED JUNK SCIENCE AND CLARITY OF THE GOOD FAITH DEFENSE PROTECTIONS FROM THE SUPREME COURT OF THE UNITED STATES OF AMERICA IN THE RUAN RULING, CASE 20-1410: FUNDAMENTALLY IGNORED BY FEDERAL DISTRICT COURTS, THE DEA, AND PROSECUTORS

“..A deep dive analysis from our series pain and the rule of law..”

The Supreme Court case of Ruan v. United States fundamentally reshaped how the government prosecutes medical professionals by establishing a **subjective knowledge standard**. This ruling dictates that prosecutors can no longer rely solely on high **pill numbers** or objective deviations from medical guidelines; instead, they must prove a practitioner **consciously intended** to act without a legitimate medical purpose. By prioritizing a doctor’s **intent to treat** over mere administrative errors, the decision creates a robust **good-faith** **defense that distinguishes legitimate clinicians from criminal drug dealers. Ultimately, the text argues that this legal shift protects the medical** **authority of** experts against ideological overreach and prevents the criminalization of complex clinical decisions.

from youarewithinthenorms.com

NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., IN THE SPIRIT OF RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS

“..In this searing critique, Julie Killingsworth denounces the 2016 CDC opioid prescribing guidelines as evidence-based junk science driven by academic ego rather than rigorous clinical evidence. She argues that influential figures like Jane Ballantyne have weaponized flawed data and arbitrary definitions to conflate legitimate chronic pain management with addiction, effectively abandoning vulnerable patients. By highlighting the lack of recent practical experience among the guidelines’ authors, Killingsworth suggests that these policies represent a naked attempt at intimidation, a destructive ideological crusade that prioritizes anti-narcotic zealotry over the lived reality of incurable suffering. Ultimately, the text serves as a call to expose the corruption and dehumanization inherent in medical protocols that treat complex physical diseases with “shady” academic guesswork..”

THE RUAN DECISION

The provided article discusses the Supreme Court’s landmark ruling in Ruan v. United States, which fundamentally changed how medical professionals are prosecuted under the Controlled Substances Act. The decision established a “good faith” defense, requiring the government to prove a practitioner subjectively knew they were acting without a legitimate medical purpose rather than just making an objective error. This high legal threshold prevents the DEA and prosecutors from using high prescription volumes alone as definitive evidence of criminal activity. By emphasizing a doctor’s intent to treat, the ruling creates a clear legal distinction between licensed medical providers and illicit drug traffickers. Ultimately, the text argues that this precedent protects physicians from wrongful criminalization caused by aggressive regulatory overreach or medical disagreements. How does Ruan distinguish medical professionals from street drug dealers?
Why are pill counts insufficient to prove a doctor’s guilt?
What challenges do prosecutors face when proving subjective intent?

The decision established a **“good faith” defense**, requiring the government to prove a practitioner **subjectively knew** they were acting without a legitimate medical purpose rather than just making an objective error. This high legal threshold prevents the **DEA and prosecutors** from using high prescription volumes alone as definitive evidence of criminal activity. By emphasizing a doctor’s **intent to treat**, the ruling creates a clear legal distinction between licensed medical providers and illicit drug traffickers.

THE GOOD FAITH DEFENSE FOR MEDICAL PRACTITIONERS

The “good faith” defense for medical practitioners is a legal protection established to ensure that doctors and pharmacists are not criminally prosecuted for medical mistakes made while attempting to treat patients. This defense was significantly strengthened by the Supreme Court’s 9-0 ruling in Ruan v. United States, yet it was all but ignored by Department of Justice Prosecutions and discarded by Federal Judges such as Chad Kenny.

Supreme Court restores the good faith defense

DECISION OF THE COURT

20-1410_1an2:DECISECION Download

Key components of this defense include:

Requirement of Subjective Knowledge: To convict a practitioner under the Controlled Substances Act (CSA), the government must prove that the defendant “subjectively knew” the prescription was issued without a legitimate medical purpose. It is not enough to show that the doctor’s actions were objectively unreasonable or didn’t meet a specific standard; the government must prove the doctor knew they were acting outside the law.
Protection Against Medical Mistakes: The sources argue that the DEA often attempts to “criminalize good faith medical mistakes” by treating them as criminal acts rather than professional errors. The “good faith” defense serves as a barrier against this, as criminal negligence cannot be established if the practitioner acted with an “intent to treat” rather than an intent to distribute drugs illegally.
Evidence Beyond “Pill Numbers”: Under this defense, “numbers alone” (such as high dosages or pill counts) cannot determine if a crime has been committed. Because a practitioner treating severe chronic pain or addiction will naturally have higher prescribing averages, the defense requires the government to look beyond data points and prove the individual’s subjective intent.
Impact on Prosecutions: This high standard of proof led to the dismissal of cases such as United States v. James Barclay, where prosecutors determined they could not meet the “beyond a reasonable doubt” standard required by the Ruan decision to establish criminal negligence.
Distinction from “Drug Dealers”: The Supreme Court decision in Ruan emphasizes that doctors and pharmacists are fundamentally different from street drug dealers because they possess formal education, are registered with the DEA, and prescribe FDA-supervised medications with the legitimate intent to treat illness. The good faith defense protects this professional status by requiring proof of criminal intent rather than just a deviation from a guideline

The Ruan decision reinforces the idea that the CSA’s structure reflects Congress’s unwillingness to cede medical authority to executive officials, such as the Attorney General or the DEA, who lack medical expertise. The ruling emphasizes that a DEA-registered practitioner’s education, conduct, and “intent to treat” fundamentally differentiate them from street drug dealers. By requiring proof of subjective knowledge of illegitimacy, the decision protects practitioners from being prosecuted as “drug dealers in white coats” for what may be good-faith medical disagreements or errors.

What are the legal implications of the Ruan decision?

The Supreme Court’s 9-0 decision in Ruan v. United States (often cited as Ruan-Khan) has established significant legal hurdles for the government in prosecuting medical practitioners under the Controlled Substances Act (CSA). According to the sources, the primary legal implications are:

1. Establishment of a Subjective Knowledge Standard

The most critical implication is the shift in the burden of proof regarding a practitioner’s intent. The Court held that for a conviction under § 841(a)(1) and § 1306.04(a), the government must prove that a defendant:

Subjectively knew that a prescription was issued without a legitimate medical purpose; or
Issued a prescription that was objectively not in the usual course of professional practice.

This means that proving a doctor merely made a mistake or deviated from a guideline is no longer sufficient for a criminal conviction; the government must prove the doctor knew their actions were unauthorized.

2. Difficulty in Proving Criminal Negligence

The decision has made the standard of proof—“beyond a reasonable doubt”—much harder for the government to meet in cases involving authorized practitioners. For example, in the case of United States v. James Barclay, prosecutors moved to dismiss the indictment because they determined they could no longer meet this higher standard of proof following the Ruan ruling.

3. Insufficiency of “Pill Numbers” for Prosecution

Under the Ruan standard, “going strictly by ‘pill’ numbers is not enough to support a prosecution”. Because a doctor’s intent to treat is now a central legal issue, data-mined metrics—like high pill counts or dosages—cannot independently serve as proof of a crime without evidence of the practitioner’s subjective state of mind.

4. Limitation of Executive Medical Judgment

The Ruan decision reinforces the concept that the structure of the CSA reflects Congress’s unwillingness to cede medical judgments to executive officials, such as the Attorney General or the DEA, who lack medical expertise. Legal arguments following this decision assert that:

A qualified professional with medical expertise must be the one to determine if a prescription is medically legitimate,.
The DEA’s internal interpretations of medical regulations (specifically 21 C.F.R. § 1306.04(a)) may not be entitled to “Auer deference” because the agency lacks the “clear congressional authorization” to make medical judgments.

5. Legal Distinction Between Doctors and Drug Dealers

The ruling emphasizes that the education, conduct, and “intent to treat” of a DEA-registered practitioner fundamentally differentiate them from street drug dealers. By requiring proof of subjective knowledge of illegitimacy, the decision protects practitioners from being prosecuted as “drug dealers in white coats” for what may actually be good-faith medical disagreements or errors.